BioAtla Investor Conference Presentation Deck

A number of key upcoming milestones in 2022 Program BA3011 Mecbotamab Vedotin BA3021 Ozuriftamab Vedotin BA3071 BA3182 bicatla CAB-ADCs Indications STS and bone sarcoma NSCLC Ovarian* NSCLC Melanoma SCCHN Ovarian* Multiple tumor types** Adenocarcinoma** Multiple tumor types** CAB-I/O CAB-Bispecifics 1H 2022 Phase 2 interim update Phase 2 interim data ✓ Phase 2 IIT dosing Phase 2 dosing Phase 2 IIT dosing Phase 1/2 dosing *Phase 2 Investigator-initiated trial combination with PD-1 (n=60) in platinum failure patients. Initial sites activated. **Anticipated indications based upon tumor target expression. 2H Phase 2 part 2 initiation Phase 2 interim data ☆ Phase 2 interim data IND submission / Phase 1 initiation BioAtla Overview | Company Confidential 13

View entire presentation